Comparing two chemotherapy combinations for newly diagnosed AML in older adults
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This study compares two chemotherapy combinations (VAH vs VA) for older adults with newly diagnosed acute myeloid leukemia (AML). The goal is to see if adding a drug called homoharringtonine (H) to the standard treatment (VA) improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 60 and 75 years old.
- You have been diagnosed with acute myeloid leukemia (AML), a type of blood cancer.
- You have not received chemotherapy for AML before, except a drug called hydroxyurea.
- You have not been treated with hypomethylating agents (like azacitidine or decitabine) for a previous blood condition.
- Your AML is not considered favorable-risk.
- Your overall health is generally stable, with manageable organ function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (venetoclax, homoharringtonine, and azacitidine) plus a growth factor to treat newly diagnosed AML in people who aren't strong enough for standard chemo. The goal is to see if this combo can help control the leukemia with fewer side effects.
This trial compares two different combinations of chemotherapy drugs for adults newly diagnosed with acute myeloid leukemia (AML). One combination uses newer targeted drugs, while the other is a standard treatment. The goal is to see which approach works better.
This trial tests a combination of two chemotherapy drugs, medium-dose cytarabine and venetoclax, as a follow-up treatment (consolidation) to keep leukemia from coming back. It is for older adults with intermediate or high-risk acute myeloid leukemia who have already achieved remission after their first round of therapy.
This trial compares two different strengths of a chemotherapy regimen that includes venetoclax (a targeted pill) for people with newly diagnosed acute myeloid leukemia (AML). The goal is to find which dose works as well or better with fewer side effects, and it may offer a more personalized treatment option for those who can tolerate intensive therapy.
This study compares two chemotherapy combinations for older adults newly diagnosed with acute myeloid leukemia (AML) that has certain gene changes (NPM1 or IDH1/IDH2). The goal is to see if the new combination works better and has fewer side effects than the standard one.
This trial tests a combination of three drugs (venetoclax, azacitidine, and homoharringtonine) followed by a donor stem cell transplant for people with intermediate- or high-risk acute myeloid leukemia (AML). The goal is to see if this approach can improve outcomes for patients who have not been treated before.
Hear when a new Acute Myeloid Leukemia (AML) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.